Trevena Stock Forecast, Price & News

+0.01 (+0.53 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.05 million shs
Average Volume3.35 million shs
Market Capitalization$312.46 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Trevena logo

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.46 out of 5 stars

Medical Sector

647th out of 2,100 stocks

Pharmaceutical Preparations Industry

316th out of 830 stocks

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Trevena (NASDAQ:TRVN) Frequently Asked Questions

Is Trevena a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena
or view top-rated stocks.

What stocks does MarketBeat like better than Trevena?

Wall Street analysts have given Trevena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Trevena

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) announced its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The biopharmaceutical company earned $0.21 million during the quarter, compared to analyst estimates of $0.55 million.
View Trevena's earnings history

How has Trevena's stock been impacted by Coronavirus (COVID-19)?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TRVN shares have increased by 173.5% and is now trading at $1.91.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TRVN?

4 Wall Street analysts have issued 1 year price objectives for Trevena's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Trevena's share price to reach $5.00 in the next year. This suggests a possible upside of 161.8% from the stock's current price.
View analysts' price targets for Trevena
or view top-rated stocks among Wall Street analysts.

Who are Trevena's key executives?

Trevena's management team includes the following people:
  • Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 58, Pay $1.14M)
  • Mr. Scott Applebaum, Chief Legal & Compliance Officer, Sr. VP of Regulatory Affairs & Corp. Sec. (Age 54, Pay $605.31k)
  • Dr. Mark A. Demitrack, Sr. VP & Chief Medical Officer (Age 63, Pay $725.67k)
  • Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. Barry Shin, Sr. VP & CFO (Age 49)
  • Mr. Michael Catalano, VP of Marketing
  • Mr. Robert T. Yoder, Sr. VP & Chief Commercial Officer (Age 55)

Who are some of Trevena's key competitors?

What other stocks do shareholders of Trevena own?

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.15%), Millennium Management LLC (1.28%), Geode Capital Management LLC (0.86%), HRT Financial LP (0.46%), Morgan Stanley (0.23%) and Renaissance Technologies LLC (0.18%).
View institutional ownership trends for Trevena

Which institutional investors are selling Trevena stock?

TRVN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Squarepoint Ops LLC, Citigroup Inc., Royal Bank of Canada, and Bank of New York Mellon Corp.
View insider buying and selling activity for Trevena
or view top insider-selling stocks.

Which institutional investors are buying Trevena stock?

TRVN stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., HRT Financial LP, Geode Capital Management LLC, Morgan Stanley, Polar Capital Holdings Plc, Goldman Sachs Group Inc., and Diametric Capital LP.
View insider buying and selling activity for Trevena
or or view top insider-buying stocks.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $1.91.

How much money does Trevena make?

Trevena has a market capitalization of $312.46 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29,370,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

What is Trevena's official website?

The official website for Trevena is

Where are Trevena's headquarters?

Trevena is headquartered at 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.